JNJ · earnings call history
Johnson & Johnson Q2 FY26 — Strong Growth Driven by New Launches and Raised Full-Year Guidance
Read the briefJohnson & Johnson Q1 FY26 — Strong Start with Raised Guidance and Pipeline Momentum
Read the briefJohnson & Johnson Q4 FY25 — Strong Growth Across Innovative Medicine and MedTech, Elevated 2026 Guidance
Read the briefJohnson & Johnson Q3 FY25 — Strong Growth Across Innovative Medicine and MedTech, Orthopaedics Spin-Off Announced
Read the briefBrowse all US companies on the earnings-call register.